C4 Therapeutics Doses First Patient in Phase 2 MOMENTUM Trial of Cemsidomide
C4 Therapeutics has dosed the first patient in its Phase 2 MOMENTUM trial of cemsidomide, an oral IKZF1/3 degrader for relapsed or refractory multiple myeloma. The study combines cemsidomide with dexamethasone following Phase 1 data that showed compelling anti-myeloma activity and a differentiated safety profile.
1. Phase 2 MOMENTUM Trial Initiation
C4 Therapeutics has administered the first dose of cemsidomide to a relapsed or refractory multiple myeloma patient in its Phase 2 MOMENTUM trial, which will combine the oral IKZF1/3 degrader with dexamethasone to evaluate objective response rate.
2. Phase 1 Data Underpinning
This trial builds on Phase 1 findings where cemsidomide demonstrated compelling anti-myeloma activity and a differentiated safety profile, providing the rationale for expanded efficacy assessment in a larger patient cohort.